glp-1 receptor agonist side effects Agonists Starting a GLP-1 medication? Knowing
Description
10.1016/j.exer.2021.108624 25 GuttenplanK
Precision Medicine in Type 2 Diabetes: Using Individualized Prediction Models to Optimize Selection of Treatment
Injectable GLP-1 receptor agonists have traditionally dominated the market due to their effectiveness and bioavailability, making them the preferred choice for many healthcare providers
Patients should contact their GP if they experience concerning symptoms and report suspected side effects via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk or via the Yellow Card app)
In clinical trials, participants taking the highest dose of Foundayo lost an average of 1517% of their body weight over 36 to 72 weeks, compared to roughly 2% in the placebo group
Other GLP-1 receptor agonists these should not be used at the same time as semaglutide
